Loading clinical trials...
Loading clinical trials...
An Open-Label, Three-Part, Two Period, Single Sequence Study to Assess the Pharmacokinetic Interaction Between Repeat Doses of Oral Casopitant and Repeat Oral Doses of Dolasetron, Granisetron or Rosiglitazone When Co-Administered in Healthy Adult Subjects
Conditions
Interventions
casopitant
dolasetron
+2 more
Locations
1
United States
GSK Investigational Site
Evansville, Indiana, United States
Start Date
July 23, 2007
Primary Completion Date
September 21, 2007
Completion Date
September 21, 2007
Last Updated
August 3, 2017
NCT06593782
NCT00405080
NCT00404274
NCT00366834
Lead Sponsor
GlaxoSmithKline
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions